Document is current

Any future updates will be listed below

430 A phase 1b/II clinical study of AK112, a PD-1/VEGF bispecific antibody, in combination with olaparib in BRCA germline wild-type platinum sensitive recurrent ovarian cancer

Crossref DOI link: https://doi.org/10.1136/jitc-2021-SITC2021.430

Published Online: 2021-11-10

Published Print: 2021-11

Update policy: https://doi.org/10.1136/crossmarkpolicy

About CrossMark